Education
About Us
Working with TipRanks
Follow Us
Abcam PLC (CH:A8C1)
:A8C1
A8C1 Stock Chart & Stats
Day’s RangeN/A
52-Week Range― - ―
Previous CloseN/A
Volume0.00
Average Volume (3M)N/A
Market Cap
CHF4.85B
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
BetaN/A
Next Earnings
Sep 15, 2025EPS EstimateN/A
Last Dividend Ex-Date
Mar 19, 2020Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
---
A8C1 FAQ
What was Abcam PLC’s price range in the past 12 months?
Currently, no data Available
What is Abcam PLC’s market cap?
Abcam PLC’s market cap is CHF4.85B.
When is Abcam PLC’s upcoming earnings report date?
Abcam PLC’s upcoming earnings report date is Sep 15, 2025 which is in 165 days.
How were Abcam PLC’s earnings last quarter?
Currently, no data Available
Is Abcam PLC overvalued?
According to Wall Street analysts Abcam PLC’s price is currently Overvalued.
Does Abcam PLC pay dividends?
Abcam PLC pays a Annually dividend of CHF0.04 which represents an annual dividend yield of N/A. See more information on Abcam PLC dividends here
What is Abcam PLC’s EPS estimate?
Abcam PLC’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Abcam PLC have?
Currently, no data Available
What happened to Abcam PLC’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Abcam PLC?
Currently, no hedge funds are holding shares in CH:A8C1
---
Company Description
Abcam PLC
Abcam PLC is a biotechnology company that develops and provides antibodies to life science research and clinical communities. The company's products allow research into the role of signaling and regulatory molecules and proteins in biological pathways. Such research ultimately leads to treatments for diseases such as cancer and immune deficiency disorders. Abcam's focused on broadening its product range, improving speed to market, and accessing underpenetrated consumer groups in its markets. The company also selectively pursues partnerships and acquisitions.
---
A8C1 Stock 12 Month Forecast
Average Price Target
―---